If validated, pl-Hp could be incorporated into cardiovascular risk assessment models for obese patients with T2DM, leading to earlier interventions, more targeted therapies, and ultimately reduced cardiovascular events in this high-risk group. The gene discussed is HP; the disease is type 2 diabetes mellitus.